1596340-59-8

Basic information

• Product Name: 2-(1-(4-((2,3-dihydro-2-phenylbenzo[b][1,4]dioxin-3-yl)methoxy)butyl)piperidin-4-yl)benzo[d]oxazole
• Synonyms: 2-(1-(4-((2,3-dihydro-2-phenylbenzo[b][1,4]dioxin-3-yl)methoxy)butyl)piperidin-4-yl)benzo[d]oxazole
• CAS NO: 1596340-59-8
• Molecular Weight: 498.622
• Mol File: 1596340-59-8.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: 2-(1-(4-((2,3-dihydro-2-phenylbenzo[b][1,4]dioxin-3-yl)methoxy)butyl)piperidin-4-yl)benzo[d]oxazole(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(1-(4-((2,3-dihydro-2-phenylbenzo[b][1,4]dioxin-3-yl)methoxy)butyl)piperidin-4-yl)benzo[d]oxazole(1596340-59-8)
• EPA Substance Registry System: 2-(1-(4-((2,3-dihydro-2-phenylbenzo[b][1,4]dioxin-3-yl)methoxy)butyl)piperidin-4-yl)benzo[d]oxazole(1596340-59-8)

Safety Data

• Hazardous Substances Data: 1596340-59-8(Hazardous Substances Data)

Upstream product

• 21770-49-0 methyl 2,3-dihydro-3-phenylbenzo[b][1,4]dioxine-2-carboxylate 
• 21770-48-9 methyl 2,3-dibromo-3-phenylpropanoate 
• 103-26-4 methyl cinnamate 
• 51784-03-3 4-(benzoxazol-2-yl)piperidine 
• 1596340-51-0 2-((4-bromobutoxy)methyl)-2,3-dihydro-3-phenyl-benzo[b][1,4]dioxane 
• 24127-63-7 (2,3-dihydro-2-phenylbenzo[b][1,4]dioxin-3-yl)methanol 

Relevant articles and documents

Benzdioxan-benzocarbazoles oxa (thia) azole piperidine derivatives and its use

The present invention belongs to the field of pharmaceutical chemistry, and particularly to a benzodioxane-benzoxazole (benzothiazole) piperidine derivative and an application thereof. According to the present invention, the benzodioxane-benzoxazole (benzothiazole) piperidine derivative is a compound represented by a general formula (I) or a medically acceptable salt thereof; and in vitro receptor binding test results show that the compound represented by the general formula (I) or the medically acceptable salt thereof provides high affinity for a 5-HT1A receptor and a 5-HT2A receptor, and animal test results show that the mouse immobility time can be significantly reduced when the compound is used in acute treatment, such that the compound provides treatment effects for neuropsychiatric diseases, particularly depression. The general formula (I) is as the follow.